Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
05/2012
05/18/2012WO2012064806A2 Methods and compositions for unsilencing imprinted genes
05/18/2012WO2012064805A1 Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
05/18/2012WO2012064774A1 An ire1alpha endonuclease specific inhibitor with cytotoxic activity
05/18/2012WO2012064744A2 Tetrahydroquinoline and related bicyclic compounds for inhibition of rorϒ activity and the treatment of disease
05/18/2012WO2012064715A1 Compositions and methods relating to heat shock transcription factor activating compounds and targets thereof
05/18/2012WO2012064697A2 Materials presenting notch signaling molecules to control cell behavior
05/18/2012WO2012064680A1 Selective glycosidase inhibitors and uses thereof
05/18/2012WO2012064667A2 Treatment of addiction and impulse-control disorders using pde7 inhibitors
05/18/2012WO2012064654A1 Methods for prevention and treatment of influenza
05/18/2012WO2012064642A1 Fatty acid synthase inhibitors
05/18/2012WO2012064632A1 Methods of treating cancer and other disorders
05/18/2012WO2012064631A1 Pyridyl ureas as mineralocorticoid receptor antagonists
05/18/2012WO2012064559A1 Sgc stimulators
05/18/2012WO2012064557A2 Deodorizing compositions
05/18/2012WO2012064548A1 Compounds useful for inhibiting chk1
05/18/2012WO2012064396A2 Novel ezrin inhibitors and methods of making and using
05/18/2012WO2012064377A1 Antifolate compositions
05/18/2012WO2012064340A1 Dual-action compounds targeting adenosine a2a receptor and adenosine transporter for prevention and treatment of neurodegenerative diseases
05/18/2012WO2012064307A1 Pharmaceutical compositions comprising rosuvastatin
05/18/2012WO2012064300A2 Desloratadine granules
05/18/2012WO2012064286A1 Targeting metabolic enzymes in human cancer
05/18/2012WO2012064269A1 COMPOUNDS AND THEIR USE FOR TREATMENT OF Αβ-RELATED DISEASES
05/18/2012WO2012064268A1 Ibat inhibitors for treatment of metabolic disorders and related conditions
05/18/2012WO2012064267A1 A pharmaceutical combination comprising an ibat inhibitor and a bile acid binder
05/18/2012WO2012064266A1 Ibat inhibitors for the treatment of liver diseases
05/18/2012WO2012064222A1 Agent for inducing endogenous interferon
05/18/2012WO2012064221A1 Drug for treating liver lesions caused by the action of chemical or biological agents
05/18/2012WO2012064159A2 Anticancer composition
05/18/2012WO2012064150A2 Composition comprising benproperine derivatives as active ingredients for preventing and treating angiogenesis-related diseases
05/18/2012WO2012064130A2 Colon-targeted celecoxib precursor compound and pharmaceutical composition containing the compound as an active ingredient for treating or preventing colonic diseases
05/18/2012WO2012064088A2 Pharmaceutical composition including polymer microsphere containing olanzapine as active ingredient
05/18/2012WO2012064087A2 Pharmaceutical composition including polymer microsphere containing anastrozole as active ingredient
05/18/2012WO2012064072A2 Composition for preventing or treating rheumatoid arthritis comprising a phospholipase d1 inhibitor as an active ingredient
05/18/2012WO2012063933A1 Crystalline 6,7-unsaturated-7-carbamoyl morphinane derivative, and method for producing same
05/18/2012WO2012063896A1 Novel pyrazole amide derivative
05/18/2012WO2012063894A1 Compositions containing antisense oligonucleotide to micro rna
05/18/2012WO2012063820A1 Suppressor for increase in blood glucose level
05/18/2012WO2012063514A1 Attractant for bone marrow stem cells, and method for attracting bone marrow stem cells
05/18/2012WO2012063513A1 Method of treatment for mental disorders
05/18/2012WO2012063487A1 Antimalarial drug comprising alaremycin or derivative thereof as active ingredient
05/18/2012WO2012063357A1 Method for producing bioactive agent, bioactive agent produced thereby, cosmetic, freshness-maintaining agent, growth promotion agent, soil conditioning agent, and pharmaceutical stock solution
05/18/2012WO2012063272A1 Defibrotide for use in prophylaxis and/or treatment of graft versus host disease (gvhd).
05/18/2012WO2012063250A1 Substituted 4-beta-acrylamidopodophyllotoxin congeners as antitumour antibiotics and the process for preparation thereof
05/18/2012WO2012063246A1 Amorphous form of lurasidone hydrochloride
05/18/2012WO2012063225A1 A pharmaceutical composition
05/18/2012WO2012063217A1 Composition for treating phonatory and olfactory apparatus disorders
05/18/2012WO2012063207A1 Lactam derivatives useful as orexin receptor antagonists
05/18/2012WO2012063182A1 Pharmaceutical composition of taxoids
05/18/2012WO2012063134A2 Cardiac glycoside analogs in combination with emodin for cancer therapy
05/18/2012WO2012063005A2 Pharmaceutical composition and dosage form comprising dronedarone, and preparation method thereof
05/18/2012WO2012062996A1 Derivatives of 6-amino-6-deoxyglucosamine and use of same as antibacterial agents
05/18/2012WO2012062951A1 Novel duganella strains isolated from rhizosphere of wild and cultivated olive trees and use thereof in the production of violacein
05/18/2012WO2012062928A1 Methods of improving mental or physical health conditions in an individual
05/18/2012WO2012062925A2 Compounds and methods for treating pain
05/18/2012WO2012062920A1 Combination therapy with an antitumor alkaloid
05/18/2012WO2012062916A1 Crystalline solifenacin succinate
05/18/2012WO2012062905A2 Chromene derivatives and their analoga as wnt pathway antagonists
05/18/2012WO2012062901A2 Chromene derivatives and their analoga as wnt pathway antagonists
05/18/2012WO2012062870A1 Uracyl spirooxetane nucleoside phosphoramidates
05/18/2012WO2012062869A1 Uracyl spirooxetane nucleoside phosphoramidates
05/18/2012WO2012062867A1 Uncharged pegylated liposomes for use as medicinal products for prophylaxis and therapy of haemorrhagic and thromboembolic disorders
05/18/2012WO2012062847A1 Use of 2',5'-oligoadenylate derivative compounds
05/18/2012WO2012062835A1 Novel pharmaceutical compositions
05/18/2012WO2012062834A1 Liquid pharmaceutical composition for the treatment of a posterior eye disease
05/18/2012WO2012062783A1 Pyrazole aminopyrimidine derivatives as lrrk2 modulators
05/18/2012WO2012062759A1 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
05/18/2012WO2012062751A1 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
05/18/2012WO2012062750A1 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS
05/18/2012WO2012062743A1 Arylaminoalcohol-substituted 2,3-dihydroimidazo[1,2-c]quinolines
05/18/2012WO2012062704A1 Pyridine compounds and aza analogues thereof as tyk2 inhibitors
05/18/2012WO2012062698A1 Pharmaceutical composition, methods for treating and uses thereof
05/18/2012WO2012062694A1 Use of 2-carboxamide cycloamino urea derivatives in the treatment of egfr dependent diseases or diseases that have acquired resistance to agents that target egfr family members
05/18/2012WO2012062691A1 Pharmaceutical compositions for treating hcv infections
05/18/2012WO2012062687A1 Triazole derivatives and their use for neurological disorders
05/18/2012WO2012062685A2 Pharmaceutical composition for treating hcv infections
05/18/2012WO2012062676A1 Lisuride, terguride and derivatives thereof for use in the prophylaxis and/or treatment of fibrotic changes
05/18/2012WO2012062653A1 Combination of bevacizumab and 2,2-dimethyl-n-((s)-6-oxo-6,7-dihydro - 5h-dibenzo[b,d]azepin-7-yl)-n'-(2,2,3,3,3-pentafluoro-propyl)-malonamide for the treatment of proliferative disorders
05/18/2012WO2012062623A1 Triazole derivatives as ligands for gaba receptors
05/18/2012WO2012062596A1 Prevention of adverse effects caused by cd3 specific binding domains
05/18/2012WO2012062463A1 Substituted bicyclic carboxamide and urea derivatives as vanilloid receptor ligands
05/18/2012WO2012062439A1 Dosing regimen for sedation with cns 7056 (remimazolam)
05/18/2012WO2012062366A1 Compositions comprising wnt inhibitors for treating cancer
05/18/2012WO2012062332A2 Novel photoinitiators
05/18/2012WO2012062210A1 Compound for increasing kinase active and application thereof
05/18/2012WO2012062187A1 Prolinamide derivative as thrombin inhibitor, preparation method and application thereof
05/18/2012WO2012062157A1 Pyrano[3,2-d]thiazol derivatives and uses thereof as selective glycosidase inhibitors
05/18/2012WO2012062044A1 Small molecule inhibitor syntelin against kinetochore motor protein cenp-e and use thereof
05/18/2012WO2012062042A1 Use of 3,8,12,14,17,20-oxo-substituted pregnene glycoside compounds in the preparation of healthcare products, food additives and pharmaceuticals for the inhibition of appetite
05/18/2012WO2012062026A1 Salts of kukoamine b, preparation method and use thereof
05/18/2012WO2012061972A1 Selective glycosidase inhibitors and uses thereof
05/18/2012WO2012061971A1 Selective glycosidase inhibitors and uses thereof
05/18/2012WO2012061958A1 Flavone derivatives and their preparative method and medical use
05/18/2012WO2012061954A1 Preparative method and use of zingiberensis saponin extracted from dioscorea zingiberensis with antitumor activity
05/18/2012WO2012061931A1 Use of geniposide in diabetes prevention
05/18/2012WO2012061927A1 Selective glycosidase inhibitors and uses thereof
05/18/2012WO2012061926A1 Bisarylsulfone and dialkylarylsulfone compounds as calcium channel blockers
05/18/2012WO2012061920A1 Topical organic acid salt compositions suitable for treating infections
05/18/2012WO2012061902A1 Micronised spray-dried particles comprising polymyxin
05/18/2012WO2012040651A3 Controlled release formulations of opioids
05/18/2012WO2012040499A3 Metabolic inhibitors
1 ... 1223 1224 1225 1226 1227 1228 1229 1230 1231 1232 1233 1234 1235 1236 1237 1238 1239 1240 1241 1242 1243 ... 7860